
GEMINI THERAPEUTICSCS INC
Share · US36870G1058 · GMTX (XNAS)
No Price
n/a
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
- | - | - | - | 0,00 % | 0,00 % | -88,84 % |
Company Profile for GEMINI THERAPEUTICSCS INC Share
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Company Data
Name GEMINI THERAPEUTICSCS INC
Company Gemini Therapeutics, Inc.
Symbol GMTX
Primary Exchange
NASDAQ

ISIN US36870G1058
Asset Class Share
Sector Healthcare
Industry Biotechnology
Market Capitalization 25 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 300 One Kendall Square, 02139 Cambridge
IPO Date 2020-08-12
Stock Splits
Date | Split |
---|---|
30.12.2022 | 1:10 |
Ticker Symbols
Name | Symbol |
---|---|
NASDAQ | GMTX |
More Shares
Investors who GEMINI THERAPEUTICSCS INC hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.